Technical Analysis for ACOR - Acorda Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Very Strong | Up | Up | Up |
Historical ACOR trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week Closing High | Bullish | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Overbought Stochastic | Strength | 0.00% | |
Up 3 Days in a Row | Strength | 0.00% | |
Up 4 Days in a Row | Strength | 0.00% | |
New 52 Week Closing High | Bullish | 5.18% | |
Jack-in-the-Box Bullish | Bullish Swing Setup | 5.18% | |
Spinning Top | Other | 5.18% | |
Upper Bollinger Band Walk | Strength | 5.18% | |
Inside Day | Range Contraction | 5.18% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time | |
---|---|---|
Jack-in-the-Box Bullish Entry | 1 day ago | |
Rose Above Previous Day's High | 1 day ago | |
Up 3% | 2 days ago | |
60 Minute Opening Range Breakout | 2 days ago | |
Up 2% | 2 days ago |
Get a Trading Assistant
- Earnings date: 02/11/2021
Acorda Therapeutics, Inc. Description
Acorda Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other central nervous system disorders primarily in the United States. Its products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The company also markets products for the improvement of walking in adult patients with MS under the Fampyra name internationally. In addition, it is developing Diazapam Nasal Spray, which is in NDA preparations for the treatment of cluster/acute repetitive seizures; Dalfampridine that is in Phase II clinical trials for cerebral palsy and post-stroke deficits; AC105, which is in Phase II clinical trials for the treatment of SCI and TBI; Neuregulin Program that has completed Phase 1 clinical trial for the treatment of heart failure; Remyelinating Antibodies Program, which is in Phase 1 clinical trial for the treatment of MS; and Chondroitinase Program that is in research for SCI. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Antibodies Autoimmune Diseases Injury Chloride Clinical Trial Spas Heart Failure Multiple Sclerosis Nervous System Disorders Central Nervous System Disorders Stroke Potassium DSL Spinal Cord Seizure Nasal Spray Seizures Spinal Cord Injury Treatment Of Heart Failure Spasticity Tbi Acorda Therapeutics Treatment Of Ms Zanaflex
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 7.18 |
52 Week Low | 0.4224 |
Average Volume | 3,400,526 |
200-Day Moving Average | 0.96 |
50-Day Moving Average | 1.56 |
20-Day Moving Average | 2.74 |
10-Day Moving Average | 4.75 |
Average True Range | 0.52 |
ADX | 60.82 |
+DI | 63.16 |
-DI | 1.23 |
Chandelier Exit (Long, 3 ATRs ) | 5.63 |
Chandelier Exit (Short, 3 ATRs ) | 2.21 |
Upper Bollinger Band | 7.06 |
Lower Bollinger Band | -1.58 |
Percent B (%b) | 0.96 |
BandWidth | 315.34 |
MACD Line | 1.37 |
MACD Signal Line | 0.91 |
MACD Histogram | 0.4561 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 7.67 | ||||
Resistance 3 (R3) | 7.56 | 7.14 | 7.50 | ||
Resistance 2 (R2) | 7.14 | 6.90 | 7.19 | 7.45 | |
Resistance 1 (R1) | 6.92 | 6.74 | 7.03 | 7.02 | 7.40 |
Pivot Point | 6.50 | 6.50 | 6.55 | 6.55 | 6.50 |
Support 1 (S1) | 6.28 | 6.25 | 6.39 | 6.38 | 6.00 |
Support 2 (S2) | 5.86 | 6.10 | 5.91 | 5.95 | |
Support 3 (S3) | 5.63 | 5.86 | 5.90 | ||
Support 4 (S4) | 5.73 |